Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Molecular Profile CD274 over exp
Therapy Cemiplimab
Indication/Tumor Type penis squamous cell carcinoma
Response Type predicted - sensitive


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 over exp penis squamous cell carcinoma predicted - sensitive Cemiplimab Case Reports/Case Series Actionable In a clinical case study, a patient with metastatic squamous cell carcinoma of the penis harboring CDKN2A R80* with high CD274 (PD-L1) expression (IHC>95%) previously treated with cisplatin-based chemotherapy and radiotherapy achieved a complete response to treatment with Libtayo (cemiplimab), and maintained the complete response six months after treatment cessation (PMID: 34267641). 34267641
PubMed Id Reference Title Details
(34267641) Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer. Full reference...